NuPulseCV
Raleigh, US · Founded 2010 · Delaware corporation · 1 known investors
NuPulseCV develops the Voyage device, a cardiac support technology aimed at patients with heart failure who are treated at both major institutions and community hospitals. The company is guided by a scientific advisory board of clinically active cardiologists and cardiac surgeons.
Founders & leadership
GS
GREG SCOTTNamed on SEC filing
RS
RICHARD SHERMANNamed on SEC filing
AS
ALEX SHLYANKEVICHNamed on SEC filing
SP
SONNA PATEL-RAMANNamed on SEC filing
DA
DOUGLAS ALTSCHULERNamed on SEC filing
BN
BRIAN NOVAKNamed on SEC filing
BN
BRIAN NOVACKNamed on SEC filing
VJ
VALLUVAN JEEVANANDAMNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$14.2M disclosed across 3 rounds · 2014–2020
▶$2.1MraisedMar 2020 · 2 investors · BiotechnologyRule 506(b)
▶$2.1MraisedMar 2020 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas AltschulerExecutive Officer, Director
- Richard ShermanDirector
- Brian NovackDirector
- Alex ShlyankevichDirector
- Greg ScottDirector
- Dirk SimmonsDirector
- Sonna Patel-RamanExecutive Officer
- Offering amount
- $20M
- Amount sold
- $2.1M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.4MraisedJul 2018 · 13 investors · BiotechnologyRule 506(b)
▶$5.4MraisedJul 2018 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- GREG SCOTTDirector
- RICHARD SHERMANDirector
- ALEX SHLYANKEVICHDirector
- SONNA PATEL-RAMANExecutive Officer
- DOUGLAS ALTSCHULERExecutive Officer, Director
- BRIAN NOVAKDirector
- Offering amount
- $25M
- Amount sold
- $5.4M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.7MraisedAug 2014 · 13 investors · BiotechnologyRule 506(b)
▶$6.7MraisedAug 2014 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- BRIAN NOVACKDirector
- RICHARD SHERMANDirector
- VALLUVAN JEEVANANDAMDirector
- DOUGLAS ALTSCHULERExecutive Officer, Director
- Offering amount
- $6.7M
- Amount sold
- $6.7M
- Minimum investment
- $150K
- First sale
- Jun 2014
- Incorporated
- Corporation, Delaware, 2010
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $256.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does NuPulseCV do?
- NuPulseCV develops the Voyage device, a cardiac support technology aimed at patients with heart failure who are treated at both major institutions and community hospitals. The company is guided by a scientific advisory board of clinically active cardiologists and cardiac surgeons.
- Who are NuPulseCV's investors?
- NuPulseCV's investors include Broadview Ventures.
- How much funding has NuPulseCV raised?
- NuPulseCV has disclosed $14.2M raised across 3 rounds.
- Where is NuPulseCV headquartered?
- NuPulseCV is headquartered in Raleigh, US.